Author | Solórzano, Victor Edgar Fiestas | |
Author | Lima, Raquel Curtinhas de | |
Author | Azeredo, Elzinandes Leal de | |
Access date | 2023-01-10T18:06:47Z | |
Available date | 2023-01-10T18:06:47Z | |
Document date | 2022 | |
Citation | SOLÓRZANO, Victor Edgar Fiestas; LIMA, Raquel Curtinhas de; AZEREDO, Elzinandes Leal de. Pathogens, v. 11, 1179, p. 1 - 21, Oct. 2022. | en_US |
ISSN | 2076-0817 | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/56426 | |
Language | eng | en_US |
Publisher | MDPI | en_US |
Rights | open access | |
Subject in Portuguese | Dengue | en_US |
Subject in Portuguese | Dengue grave | en_US |
Subject in Portuguese | Fator de crescimento | en_US |
Subject in Portuguese | Análise | en_US |
Title | The Role of Growth Factors in the Pathogenesis of Dengue: A Scoping Review | en_US |
Type | Article | |
DOI | 10.3390/ pathogens11101179 | |
Abstract | Growth factors (GFs) have a role in tissue repair and in the modulation of the expression
of inflammatory cells in damage caused by pathogens. This study aims to systematize the evidence
on the role of GFs in the pathogenesis of dengue. This scoping review considered all published
peer-reviewed studies in the MEDLINE and Embase databases. Ultimately, 58 studies that analyzed
GFs in dengue patients, published between 1998 and 2021, were included. DENV-2 infection and
secondary infection were more frequent in the patients studied. ELISA and multiplex immunoassay
(Luminex) were the most used measurement techniques. Increased levels of vascular endothelial
growth factor, granulocyte–macrophage colony-stimulating factor, granulocyte colony-stimulating
factor, transforming growth factor beta, and hepatocyte growth factor as well as reduced levels
of platelet-derived growth factor and epidermal growth factor were observed in severe dengue in
most studies. Vascular endothelial growth factor and hepatocyte growth factor were identified as
biomarkers of severity. In addition, there is evidence that the dengue virus can use the growth factor
pathway to facilitate its entry into the cell and promote its viral replication. The use of tyrosine kinase
inhibitors is an alternative treatment for dengue that is being studied. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunologia Viral. Rio de Janeiro, RJ, Brasil. | en_US |
Subject | Dengue | en_US |
Subject | Severe dengue | en_US |
Subject | Growth factor | en_US |
Subject | Review | en_US |